GATA3
GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
Overview
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Cobimetinib. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes affected pathway 0.56, literature 0.99, genetic association 0.37, somatic mutation 0.87, animal model 0.65). IntOGen calls it a driver in 7 cohorts (3 activating, 3 loss-of-function), covering Acute Lymphoblastic Leukaemia, Invasive Breast Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
- 1 · What it is
GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
- 2 · What goes wrong in cancer
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'.
- 3 · How drugs use it
No product in this corpus aims at GATA3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:4172 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23771 (protein name, function text, keywords and locations (REST API)); CIViC gene GATA3 (1 evidence items, 0 assertions, 1 variants; diseases: Histiocytosis-Lymphadenopathy Plus Syndrome (GraphQL API, CC0)); Open Targets ENSG00000107485 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.62, Hodgkins lymphoma 0.51, non-Hodgkin lymphoma 0.66, breast cancer 0.74, leukaemia 0.66 (GraphQL API, CC0)); IntOGen GATA3 (driver in 7 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. Positively regulates ASB2 expression. Coordinates macrophage transcriptional activation and UCP2-dependent metabolic reprogramming in response to IL33. Upon tissue injury, acts downstream of IL33 signalling to drive differentiation of inflammation-resolving alternatively activated macrophages. Location: Nucleus (UniProt). Locus 10p14 (HGNC).
- Breast cancer: Open Targets association 0.74 with breast cancer (MONDO_0007254); IntOGen driver in 6 cohorts (BRCA)
- Non-Hodgkin lymphoma: Open Targets association 0.66 with non-Hodgkin lymphoma (MONDO_0018908)
- Leukaemia: Open Targets association 0.66 with leukaemia (MONDO_0005059)
- Hodgkin lymphoma: Open Targets association 0.51 with Hodgkins lymphoma (MONDO_0004952)
- Acute lymphoblastic leukaemia: Open Targets association 0.62 with acute lymphoblastic leukaemia (MONDO_0004967); IntOGen driver in 1 cohort (ALL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Histiocytosis-Lymphadenopathy Plus Syndrome.
Latest papers
topQuery for this target: (TITLE:"GATA3" OR ABSTRACT:"GATA3" OR TITLE:"GATA binding protein 3" OR ABSTRACT:"GATA binding protein 3" OR TITLE:"Trans-acting T-cell-specific transcription factor GATA-3" OR ABSTRACT:"Trans-acting T-cell-specific transcription factor GATA-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GATA3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNT5C2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetCTCF
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetCCND3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetLEF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetTBL1XR1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetETV6
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.